Oral presentation on the positive Phase 3 SAPPHIRE trial of apitegromab for people living with spinal muscular atrophy (SMA), which demonstrated statistically significant improvement and clinically meaningful benefit as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE) Apitegromab Biologics License Application (BLA) accepted under priority review for patients with SMA, and U.S. Food and Drug Administration... Read More

Patients receiving apitegromab with tirzepatide over 24 weeks showed a 54.9% preservation of lean mass (+4.2 lbs of lean mass) versus tirzepatide alone (p=0.001) Patients receiving apitegromab with tirzepatide over 24 weeks lost 18.8 lbs of fat mass while those on tirzepatide alone lost 17.7 lbs of fat mass Patients receiving apitegromab with tirzepatide over 24 weeks lost 12.3% of body weight while those on tirzepatide... Read More

CAMBRIDGE, Mass. / Jun 13, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 309,700 shares of its common stock to 11... Read More

CAMBRIDGE, Mass. / Jun 05, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that David L. Hallal, Chief Executive Officer, and members of management will participate in a fireside chat at the 46 th Annual... Read More

Rebecca McLeod brings exceptional U.S. operating experience; most recently served as argenx U.S. General Manager responsible for leading the launch of VYVGART® for gMG and CIDP CAMBRIDGE, Mass. / Jun 02, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and... Read More

CAMBRIDGE, Mass. / May 28, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that David L. Hallal, Chief Executive Officer, and members of the management team will participate in a fireside chat at the Jefferies... Read More

CAMBRIDGE, Mass. / May 16, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 105,700 shares of its common stock to 14... Read More

Apitegromab BLA accepted under priority review for patients with Spinal Muscular Atrophy (SMA) and FDA’s PDUFA date set for September 22, 2025; commercial readiness progresses European Medicines Agency validated Marketing Authorisation Application (MAA) for apitegromab for patients with SMA Topline results from Phase 2 EMBRAZE proof-of-concept trial in adult patients with obesity on track for June 2025 Cash, cash equivalents... Read More

CAMBRIDGE, Mass. / May 07, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that management will host a conference call to discuss its first quarter 2025 financial results and provide a business update on Wednesday, May 14, 2025, at 8:15am ET.... Read More

CAMBRIDGE, Mass. / May 06, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the company granted inducement equity awards to R. Keith Woods, its newly named Chief Operating Officer and Vikas Sinha, its newly named Chief... Read More

David Hallal has served as Chairman of the Board of Directors since 2017; ensures seamless transition ahead of global launch of apitegromab for Spinal Muscular Atrophy Jay Backstrom, M.D., to serve as strategic advisor as part of planned transition, continuing to work closely with executive team and Board of Directors Akshay Vaishnaw, M.D., Ph.D., appointed to newly created role of President of R&D; has served as Board... Read More

CAMBRIDGE, Mass. / Apr 18, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the company granted inducement equity awards covering an aggregate of 156,650 shares of its common stock to 19 newly hired employees, consisting of... Read More

Apitegromab remains on track to be the first and only muscle-targeted treatment for people living with Spinal Muscular Atrophy FDA to review BLA application under priority review, with a PDUFA date of September 22, 2025 Apitegromab Marketing Authorisation Application to the European Medicines Agency validated and under review CAMBRIDGE, Mass. / Mar 25, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage... Read More

Primary endpoint showed clinically meaningful improvement in patients with SMA receiving apitegromab as measured by gold standard Hammersmith Functional Motor Scale Expanded (HFMSE) versus placebo (p=0.0192), with consistent outcomes across all major sub-groups including age, SMN-targeted background therapy, and age at initiation of SMN-targeted therapy Pre-specified secondary endpoint showed that 30.4% of patients receiving... Read More

CAMBRIDGE, Mass. / Mar 14, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 113,800 shares of its... Read More

Submitted apitegromab U.S. Biologics License Application (BLA) for patients with spinal muscular atrophy in January 2025; U.S. launch anticipated in 4Q 2025 Remain on track to submit European Union marketing authorisation application (MAA) in 1Q 2025 Topline data from Phase 2 EMBRAZE trial evaluating apitegromab vs placebo in adult patients with obesity receiving tirzepatide expected in 2Q 2025 Filing of IND application for... Read More

CAMBRIDGE, Mass. / Feb 25, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: TD Cowen 45 th Annual... Read More

Oral presentation to include additional efficacy data from the Phase 3 SAPPHIRE trial of apitegromab in patients with spinal muscular atrophy (SMA) Poster presentations include preclinical data on a combination treatment approach for building muscle mass and strength in a Duchenne muscular dystrophy (DMD) model CAMBRIDGE, Mass. / Feb 21, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical... Read More

CAMBRIDGE, Mass. / Feb 14, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 371,500 shares of its... Read More

CAMBRIDGE, Mass. / Feb 10, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its fourth quarter and full year 2024 financial... Read More

Scholar Rock’s BLA submission is based on the Phase 3 SAPPHIRE trial that demonstrated a statistically significant improvement in motor function for patients receiving apitegromab compared to placebo, as measured by the Hammersmith Functional Motor Scale-Expanded at week 52 The FDA has granted apitegromab Fast Track, Orphan Drug and Rare Pediatric Disease Designations in SMA Scholar Rock remains on track to submit the... Read More

Lisa Wyman brings more than 20 years of leadership and functional experience to new role of Chief Technical and Quality Officer on the Executive Team at Scholar Rock Ted Myles, Chief Operating Officer & Chief Financial Officer, will continue to operate through transition phase to a new organizational structure CAMBRIDGE, Mass. / Jan 29, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical... Read More

CAMBRIDGE, Mass. / Jan 17, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 48,000 shares of its... Read More

Scholar Rock Highlights 2025 Strategic Priorities BLA and MAA submission for apitegromab in SMA on track for 1Q 2025; if approved, U.S. launch expected in 4Q 2025 Initiating Phase 2 OPAL clinical trial in SMA patients under two years old in mid-2025 Data from Phase 2 EMBRAZE trial evaluating apitegromab in obesity expected in 2Q 2025 Filing of IND application for SRK-439 on track for 3Q 2025 Presenting at the 43rd Annual... Read More

CAMBRIDGE, Mass. / Jan 02, 2025 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14,... Read More

CAMBRIDGE, Mass. / Dec 13, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 208,800 shares of its... Read More

CAMBRIDGE, Mass. / Nov 15, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 100,500 shares of its... Read More

Reported positive topline data from pivotal Phase 3 SAPPHIRE trial evaluating apitegromab in patients with Spinal Muscular Atrophy (SMA), achieving primary endpoint On track to submit a U.S. Biologics License Application (BLA) and European Union marketing authorisation application (MAA) in 1Q 2025 Phase 2 EMBRAZE trial enrollment completed for apitegromab in obesity with topline data expected in 2Q 2025 Successful completion... Read More

Preclinical data show that SRK-439 increased lean mass and lowered fat mass gain in mice receiving metformin Data support that Scholar Rock’s unique approach to selective myostatin inhibition could improve body composition in people living with obesity and on an existing background treatment Scholar Rock’s industry-leading anti-myostatin portfolio includes SRK-439 and apitegromab, the first investigational anti-myostatin... Read More

CAMBRIDGE, Mass. / Nov 01, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2024 financial results and provide... Read More

CAMBRIDGE, Mass. / Oct 31, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: Truist Securities BioPharma... Read More

Poster presentation to include new safety, efficacy, and biomarker data from the long-term expansion phase of the DRAGON trial in patients with advanced solid tumors treated with SRK-181 CAMBRIDGE, Mass. / Oct 31, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious... Read More

CAMBRIDGE, Mass. / Oct 22, 2024 / Business Wire / Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that on October 16, 2024, the underwriters of its previously announced underwritten... Read More

CAMBRIDGE, Mass. / Oct 18, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 23,500 shares of its... Read More

CAMBRIDGE, Mass. / Oct 08, 2024 / Business Wire / Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the pricing of an upsized underwritten public offering of 10,265,488 shares of its... Read More

CAMBRIDGE, Mass. / Oct 07, 2024 / Business Wire / Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that it has commenced an underwritten public offering for $275 million of shares of its... Read More

Apitegromab met primary endpoint with statistically significant and clinically meaningful improvement in motor function as measured by the gold standard Hammersmith Functional Motor Scale Expanded (HFMSE) for patients with SMA receiving apitegromab versus placebo (current standard of care) at week 52 30.4% of patients receiving apitegromab had > 3 point improvement in HFMSE versus 12.5% of patients on placebo Patients... Read More

CAMBRIDGE, Mass. / Sep 13, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 407,000 shares of its... Read More

Topline results expected in 2Q 2025 CAMBRIDGE, Mass. / Sep 10, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it has completed enrollment in the Phase 2 EMBRAZE trial designed to... Read More

CAMBRIDGE, Mass. / Sep 04, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the appointment of Beth Shafer, Ph.D., to the newly created role of Chief Business Officer. Ms. Shafer... Read More

CAMBRIDGE, Mass. / Aug 29, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences in September: Morgan Stanley... Read More

CAMBRIDGE, Mass. / Aug 16, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 85,200 shares of its... Read More

Remains on track to report topline data from pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy (SMA) in 4Q 2024 New data from Phase 2 TOPAZ extension study in patients with nonambulatory SMA showed sustained clinical benefit over 48 months, a continued favorable safety profile with no new safety findings; patient retention rate of over 90% Phase 2 EMBRAZE proof-of-concept trial enrolling ahead of... Read More

CAMBRIDGE, Mass. / Jul 23, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its second quarter 2024 financial results and provide... Read More

CAMBRIDGE, Mass. / Jul 12, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards on July 10, 2024, covering an aggregate of... Read More

SRK-439, a myostatin inhibitor, is part of Scholar Rock’s industry-leading anti-myostatin portfolio Obesity program continues to progress, with first participants dosed in Phase 2 EMBRAZE trial of apitegromab in obesity CAMBRIDGE, Mass. / Jun 24, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA),... Read More

CAMBRIDGE, Mass. / Jun 18, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 96,700 shares of its... Read More

Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patients Analysis of baseline biomarker data in clear cell renal cell carcinoma (ccRCC) patients reveals a doubling of the ORR highlighting a potential patient selection strategy SRK-181 combination with pembrolizumab was generally well tolerated Company holding conference call to discuss data with Dr. Toni Choueiri on... Read More

Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3 rd , at 1:50 p.m CDT/2:50 p.m. EDT Company will host conference call to discuss the data on Tuesday, June 4 th at 7:00 a.m. CDT/8:00 a.m. EDT CAMBRIDGE, Mass. / May 28, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular... Read More

Phase 2 EMBRAZE proof-of-concept trial designed to assess apitegromab's ability to safely preserve lean muscle mass in individuals on GLP-1 receptor agonist therapy for obesity New preclinical head-to-head comparison shows that SRK-439 is more potent than an anti-ActRII antibody in maintaining lean mass in diet-induced obesity (DIO) mice; lean mass loss with SRK-439, 1mg/kg dose was equivalent to anti-ActRII antibody,... Read More

CAMBRIDGE, Mass. / May 20, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences in June: UBS Obesity... Read More

CAMBRIDGE, Mass. / May 17, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 102,150 shares of its... Read More

CAMBRIDGE, Mass. / May 14, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will host an Investor Day on Wednesday, May 22, 2024 beginning at 8:30 a.m. ET in New York City. The... Read More

On track to report topline data from pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy in 4Q 2024 Initiating Phase 2 proof-of-concept trial evaluating apitegromab in obesity in June 2024 Updated SRK-181 clinical data selected for oral presentation at American Society of Clinical Oncology (ASCO) New SRK-439 preclinical data selected for oral presentation at American Diabetes Association (ADA) Cash, cash... Read More

CAMBRIDGE, Mass. / Apr 12, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 45,000 shares of its... Read More

Pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy on track to report topline data in 4Q 2024 Announced FDA clearance of IND application to initiate Phase 2 proof-of-concept trial with apitegromab to treat obesity; expected to commence in mid-2024 Presented preclinical data supporting potential benefit of SRK-439 to preserve lean muscle mass as part of healthier weight management at Keystone Symposia... Read More

CAMBRIDGE, Mass. / Mar 15, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards on March 11, 2024, covering an aggregate of... Read More

CAMBRIDGE, Mass. / Feb 28, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in and attend the following upcoming investor conferences in March: TD... Read More

CAMBRIDGE, Mass. / Feb 16, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 131,688 shares of... Read More

CAMBRIDGE, Mass. / Feb 15, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the appointment of Katie Peng to Scholar Rock’s Board of Directors and the promotion of Mo Qatanani, Ph.D.,... Read More

Preclinical findings presented at Keystone Symposia show lean mass preservation, fat mass loss, and improved glucose metabolism Scholar Rock’s novel myostatin inhibitor, SRK-439, is part of its growing, industry-leading portfolio of innovative, highly selective anti-myostatin treatments under development CAMBRIDGE, Mass. / Feb 06, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company... Read More

SRK-439 is a novel selective myostatin inhibitor designed for the treatment of cardiometabolic disorders Preclinical data supports the potential of SRK-439 to preserve lean muscle mass as part of healthy weight loss CAMBRIDGE, Mass. / Jan 25, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic... Read More

Randomized Phase 2 proof-of-concept trial with apitegromab in patients with obesity on GLP-1 therapies on track to initiate mid-2024 Study aims to show the importance of selective myostatin inhibition in preservation of lean muscle mass as part of healthy, safe weight loss management Scholar Rock is also developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity... Read More

CAMBRIDGE, Mass. / Jan 12, 2024 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 26,250 shares of its common stock to one newly hired employee, consisting of inducement... Read More

Advancing industry-leading antimyostatin pipeline, comprised of multiple, novel assets with unparalleled selectivity, to treat spinal muscular atrophy (SMA) and cardiometabolic disorders Completed enrollment for apitegromab pivotal Phase 3 SAPPHIRE trial in patients with SMA; topline data anticipated in 4Q 2024 Apitegromab Phase 2 proof-of-concept trial in obesity expected to commence in mid-2024 Presenting new preclinical... Read More

CAMBRIDGE, Mass. / Dec 19, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 42 nd Annual Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m. ET). A live webcast of the presentation... Read More

CAMBRIDGE, Mass. / Dec 15, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 78,576 shares of its common stock to 6 newly hired employees, consisting of inducement... Read More

CAMBRIDGE, Mass. / Nov 17, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 13,125 shares of its common stock to one newly hired employee, consisting of inducement... Read More

Completed enrollment for pivotal Phase 3 SAPPHIRE trial evaluating apitegromab; topline data expected in 4Q 2024 Expanding into cardiometabolic disorders with SRK-439, a novel investigational myostatin inhibitor Presented new data supporting proof of concept for SRK-181 in heavily pretreated patients with resistant metastatic ccRCC; completing enrollment of the Phase 1 DRAGON trial in December 2023 Completed $98 million... Read More

Promising anti-tumor activity in heavily pretreated clear cell renal cell carcinoma (ccRCC) patients Objective response rate (ORR) of 21.4% and disease control rate of 57% Biomarker data supports proof of mechanism across multiple tumor types Combination therapy of SRK-181 and pembrolizumab was generally well tolerated Company to discuss SRK-181 program during conference call on third quarter 2023 financial results and... Read More

CAMBRIDGE, Mass. / Nov 02, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: Truist Securities BioPharma Symposium on Thursday, November 9, 2023, from 10:45-11:30 a.m. ET.... Read More

Poster presentations to include safety, efficacy, and biomarker data from Part A and B of the DRAGON trial in patients with advanced solid tumors treated with SRK-181 CAMBRIDGE, Mass. / Oct 19, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced today that it will... Read More

CAMBRIDGE, Mass. / Oct 11, 2023 / Business Wire / Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the pricing of an upsized underwritten public offering of 12,408,760 shares of its common stock at a public offering price of $6.85 per share. The aggregate... Read More

CAMBRIDGE, Mass. / Oct 11, 2023 / Business Wire / Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it has commenced an underwritten public offering for $75.0 million of shares of its common stock. All of the shares are being offered by Scholar Rock. In... Read More

Company plans to expand into cardiometabolic disorders, leveraging its experience in myostatin inhibition Preclinical data support advancing SRK-439, a novel investigational myostatin inhibitor for the treatment of cardiometabolic disorders, with an initial focus on obesity, towards an IND submission in 2025 To inform the development of SRK-439, Company plans to initiate a Phase 2 proof-of-concept trial of apitegromab in... Read More

Topline data from Phase 3 trial expected in Q4 2024 Company to present encore 36-month efficacy, safety, and patient-reported outcomes data from the Phase 2 TOPAZ trial extension at the 2023 World Muscle Society (WMS) Annual Congress Apitegromab is the only muscle-targeted therapy candidate with clinical data showing proof of concept in spinal muscular atrophy CAMBRIDGE, Mass. / Sep 19, 2023 / Business Wire / Scholar Rock... Read More

CAMBRIDGE, Mass. / Sep 15, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 8,750 shares of its common stock to one newly hired employee, consisting of inducement... Read More

CAMBRIDGE, Mass. / Aug 18, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 150,938 shares of its common stock to 8 newly hired employees, consisting of inducement... Read More

Recently presented 36-month apitegromab extension data from Phase 2 TOPAZ trial demonstrate long-term substantial and sustained improvement of motor function and further strengthen conviction in pivotal Phase 3 SAPPHIRE trial Pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track to complete enrollment in Q3 2023 with top-line data expected in 2H 2024 Clinical and biomarker update from the Part B portion of the Phase... Read More

CAMBRIDGE, Mass. / Jul 13, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 72,625 shares of its common stock to 6 newly hired employees, consisting of inducement... Read More

Improvements in patient-reported outcomes consistent with gains in motor function scores Safety profile at 36 months consistent with previous reports with no new safety findings; more than 90 percent of nonambulatory patients remained on study Enrollment progressing in pivotal Phase 3 SAPPHIRE registrational trial, anticipated completion in Q3 2023 Scholar Rock to host virtual investor event on July 12 at 9:00 AM EST to... Read More

CAMBRIDGE, Mass. / Jun 15, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 216,563 shares of its common stock to 8 newly hired employees, consisting of inducement... Read More

CAMBRIDGE, Mass. / Jun 01, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3:00 p.m. ET. A live webcast of the presentation may be accessed by visiting the... Read More

CAMBRIDGE, Mass. / May 10, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 49,176 shares of its common stock to four newly hired employees, consisting of inducement... Read More

Enrollment of pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track for completion in 2023 Upcoming presentations of 36-month apitegromab data from Phase 2 TOPAZ trial at Cure SMA’s Annual Research & Clinical Conference Continued advancement of Phase 1 DRAGON trial of SRK-181; biomarker and clinical data update planned in the second half of 2023 Approximately $275 million in cash, cash equivalents, and marketable... Read More

Apitegromab is the only muscle-targeted therapy to demonstrate proof of concept in spinal muscular atrophy Two oral presentations to cover long-term efficacy, safety, and patient-reported outcome data CAMBRIDGE, Mass. / May 08, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental... Read More

CAMBRIDGE, Mass. / Apr 12, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 83,125 shares of its common stock to five newly hired employees, consisting of inducement... Read More

CAMBRIDGE, Mass. / Apr 10, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Richard Brudnick, has been appointed to Scholar Rock’s Board of Directors... Read More

CAMBRIDGE, Mass. / Mar 15, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 26,250 shares of its common stock to 1 newly hired employee, consisting of inducement... Read More

CAMBRIDGE, Mass. / Mar 01, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced it will present data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24 months of treatment with apitegromab, an investigational selective... Read More

CAMBRIDGE, Mass. / Feb 27, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Cowen 43 rd Annual Health Care Conference on Tuesday, March 7, 2023, at 12:50 p.m. ET. A live webcast of the presentation may be accessed by... Read More

CAMBRIDGE, Mass. / Feb 17, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 285,000 shares of its common stock to two newly hired employees, consisting of inducement... Read More

CAMBRIDGE, Mass. / Feb 06, 2023 / Business Wire / Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Tracey M. Sacco as Chief Commercial Officer. Ms. Sacco brings extensive biopharmaceutical industry experience, including product launch and global commercial... Read More

Pivotal Phase 3 SAPPHIRE trial enrollment completion expected in 2023 Phase 1 DRAGON trial of SRK-181 continues to advance with presented data that showed early indications of efficacy; ongoing clinical data updates planned in 2023 Anticipated cash runway into 2025 Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play... Read More

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 41 st Annual Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. PT (4:30 p.m. ET). A live webcast of the presentation may be accessed by visiting the Investors & Media... Read More